Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection

  • STATUS
    Recruiting
  • End date
    Oct 27, 2023
  • participants needed
    138
  • sponsor
    Heidelberg ImmunoTherapeutics GmbH
Updated on 27 January 2021
immunoglobulin
herpes infection

Summary

This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included.

The patients need to present with 3 herpes lesions within a 9 months observation phase. With the occurrence of the third lesion, the patients will enter the 12 months treatment phase and will be randomized in a 2:1 ratio to topical HDIT or placebo applied over 2 days. A potential fourth lesion will also be treated with the blinded study medication and additional lesions will be documented.

In a 12 months post-trial follow-up phase, further information on the occurence of lesions will be collected 4 times by phone.

Study duration per patient will be up to 21 months plus 12 months post-trial follow-up by phone. Patients need to come for study visits up to 9 times.

Description

This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo.

Approximately 138 eligible patients will be randomised at a ratio of 2:1 to topical HDIT or corresponding placebo.

The trial consists of 3 parts: An observation phase (up to 9 months), a treatment phase of 12 months, and a post-trial follow-up phase of additional 12 months: The observation phase ensures that the patient develops a minimum number of lesions during the trial. In the 12 months treatment phase, blinded study treatment consisting of topical HDIT101 or placebo is applied to the patients at the first and second lesion episode. After completion of the treatment phase, patients are followed for additional 12 months for assessment of the development of further lesions (post-trial follow-up phase).

Observation phase (max. 9 months):

Eligible patients suffering from chronic recurrent herpes orolabialis for at least 12 months and reporting 6 lesions in the last 12 months can enter the observation phase. This part of the study serves for confirmation that patients develop a minimum number of 3 lesions within the 9 months observation period. No study treatment is applied in the observation phase, but standard-of-care treatment (SoC) can optionally be applied. Single swabs should additionally be taken from the lesion for confirmation of HSV-1 positivity.

Patients not developing 3 lesions with an HSV lesion score 3-7 during the 9 months observation phase are considered screening failures and will not be randomised into the treatment part of the trial.

Randomised, double-blind treatment phase (12 months):

This phase consists of four scheduled visits (day 30/120/240/365) and unscheduled visits for treatment of lesion 3 and 4, respectively.

Patients who have developed 3 outbreaks within the observational phase will enter the treatment phase. The third of these lesions will already be treated. Notably, patients do not have to complete the 9 months observation phase if they develop the 3rd lesion earlier - treatment starts with occurrence of a 3rd lesion.

With the occurrence of lesion 3 within the 9 months observation phase, patients need to schedule a visit at the study site when a vesicle is present. If the patient meets all inclusion criteria, randomisation takes place. An electronic patient reported outcome (ePRO) tool will be installed on the patients' devices and questionnaires will be answered. The lesion will be documented in the ePRO app with a photo. A swab of the lesion will be taken which preferably should contain fluid from the vesicular lesion. Subsequently, blinded IMP will be applied to the lesion. The investigator will determine the lesion start and end date based on information provided by the patient. 3 additional vials of study IMP for further treatment of this lesion will be handed over to the patient for self-application.

Upon occurrence of a fourth lesion in the treatment phase, the same procedure will be repeated at another unscheduled visit at the site when a vesicle is present. Again, IMP will be handed over to the patient for further treatment of this lesion.

All subsequent lesions occurring during the 12 months treatment phase need to be documented by the patient by photos and questionnaires. At each lesion episode, single swabs will be taken, but no further IMP will be applied and no unscheduled visit is necessary, but phone calls. The investigator will assess and medically confirm the lesion to be herpes-related and will determine the lesion start and end date based on information and photos provided by the patient and patient entries in the ePRO. Standard-of-care treatment (SoC) can optionally be applied.

Treatments and Examinations during the Study:

During all phases of the trial, patients need to report disease-specific symptoms and outbreak impact upon recognition of first symptoms during the study.

Orolabial viral shedding of patients is assessed by quantitative real time polymerase chain reaction (qRT-PCR) derived from swabs. These will be taken daily for 28 days in the orolabial region during the 9 months observation period starting after lesion 2, at occurrence of lesion 3 at visit 3 and 4 months after randomisation (starting at visit 5), respectively.

Each lesion recurrence has to be documented by the patient in the patient eDiary. In case of development of new lesions after lesion 3 or 4, patients will be instructed to take a swab of the lesion and provide this to the site for HSV-1 PCR outbreak confirmation. The patients must take photos (preferably daily) of the lesion until healing. These photos will be transferred to the sites' source data. The investigator will assess and medically confirm the lesion to be herpes-related and will determine the lesion start and end date based on information and photos provided by the patient and patient entries in the electronic diary.

Lesions will be rated according to a lesion score. For every lesion episode (outbreak), patients will be asked to report disease specific symptoms and outbreak impact in electronic questionnaires on a daily basis, from recognition of first symptoms until complete resolution of the symptoms.

Post-trial follow-up phase (12 months):

After the treatment phase, patients are further followed-up by phone every 3 months for a total duration of additional 12 months.

Details
Condition Herpes Labialis, Herpes Simplex, Cold Sores (Herpes Labialis Infections), Herpes Simplex Infections, cold sores
Treatment HDIT101 (blinded therapy), Placebo (blinded therapy), Photo documentation of orolabial herpes lesions, Completion of questionnaires (patient-reported outcomes), 28-day swabbing of orolabial region, Blood drawings
Clinical Study IdentifierNCT04539483
SponsorHeidelberg ImmunoTherapeutics GmbH
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Herpes Simplex or Cold Sores (Herpes Labialis Infections) or Herpes Labialis or Herpes Simplex Infections?
Do you have any of these conditions: Herpes Labialis or Cold Sores (Herpes Labialis Infections) or cold sores or Herpes Simplex Infections or Herpes Simplex?
Do you have any of these conditions: Herpes Simplex or Cold Sores (Herpes Labialis Infections) or Herpes Simplex Infections or Herpes Labialis or cold sores?
Do you have any of these conditions: cold sores or Cold Sores (Herpes Labialis Infections) or Herpes Simplex Infections or Herpes Simplex or Herpes Labialis?
Ability to provide written, personally signed and dated informed consent
Age 18 years
Understanding, ability, and willingness to fully comply with study interventions and restrictions
Seropositive for HSV-1 at screening with a history of chronic recurrent orolabial herpes infection for at least 12 months with at least 6 orolabial recurrences in the last year
Three confirmed lesions within 9 months after enrolment
Willingness not to use any HSV-suppressant therapy except 5% aciclovir cream as optional standard of care
Willingness to remove beard or lip piercings if lesion boundaries in this region cannot be evaluated and topical treatment of the entire lesion is compromised (according to judgement of investigator)
Willingness to self-obtain daily swabs from the orolabial region, to provide photos of the lesions and to complete questionnaires during the study
Medical assessment with no clinically significant morbidities or abnormalities as per judgement of the investigator
Willingness to use contraceptive methods
Availability of a mobile phone with a camera, connection to the internet and willingness to use this device for documentation of patient-reported outcomes and photo upload

Exclusion Criteria

Patients who do not develop at least 3 lesions during the 9 months observation phase
Herpes keratitis
Requirement for immunosuppressive therapy and/or steroids
Any known allergies to drugs or any history of severe allergic or anaphylactic reactions OR any other clinically significant allergies (mild forms, e.g. mild hay fever, are acceptable, if currently asymptomatic without treatment)
Positive HIV antibody screen, active hepatitis B virus or active hepatitis C virus infection
Treatment with an investigational drug in any clinical study within the last 30 days prior to enrolment in this study
Prior treatment with HDIT101, e.g. in this or another clinical study
Prior vaccination with an HSV type 1/2 vaccine (e.g. experimental) within the last 2 years prior screening
Pregnant or breast-feeding women
Prior malignant disease (except basal cell carcinoma in situ) if not successfully cured more than 5 years before enrolment
Patients who have abnormal skin conditions which are considered clinically significant according to the assessment of the investigator
Any clinically relevant medical history or current physical or psychiatric illnesses/medical conditions that constitute an unacceptable risk for study participation or make the participant unlikely to fully complete the study in the judgment of the investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note